Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus oral etoposide for platinum-resistant recurrent ovarian cancer
ChiCTR-IIR-17012870Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Jan 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib and etoposide in ovarian cancer (2 arms), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoints: Disease control rate and Objective response rate. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
Rivoceranibetoposide
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR-IIR-17012870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17012870.